These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7572797)

  • 21. [Diagnosis of thrombophilia based on coagulation and genetic studies].
    Bałszan-Kowalska I
    Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to activated protein C: a common anticoagulant deficiency in patients with venous leg ulceration.
    Munkvad S; Jørgensen M
    Br J Dermatol; 1996 Feb; 134(2):296-8. PubMed ID: 8746345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulant response to activated protein C: method validation and assay comparison.
    Calkins T; Greengard J; Griffin JH; Bylund D
    J Clin Lab Anal; 1995; 9(6):418-23. PubMed ID: 8587012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Instrument effect on the activated protein C resistance plasma assay performed by a commercial kit.
    De Stefano V; Paciaroni K; Mastrangelo S; Rutella S; Bizzi B; Leone G
    Thromb Haemost; 1996 May; 75(5):752-6. PubMed ID: 8725718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
    Bergrem A; Dahm AE; Jacobsen AF; Mowinckel MC; Sandvik L; Sandset PM
    Br J Haematol; 2011 Jul; 154(2):241-7. PubMed ID: 21564075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
    Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
    Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneity of the APC-resistance phenomenon.
    Bokarewa M; Blombäck M
    Thromb Res; 1994 Aug; 75(4):395-400. PubMed ID: 7997977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations].
    Trossaërt M; Conard J; Horellou MH; Samaha M; Elalamy I; Samama MM
    Presse Med; 1995 Jan; 24(4):209-12. PubMed ID: 7899365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
    Rosén S; Johansson K; Lindberg K; Dahlbäck B
    Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
    Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
    Hayashi K; Sone T; Kondoh J; Tsuboi H; Sassa H; Numaguchi Y; Toki Y; Okumura K; Ito T; Hayakawa T
    Jpn Heart J; 1997 Nov; 38(6):769-78. PubMed ID: 9486929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on relationship of activated protein C resistance and recurrent spontaneous abortion].
    Dong W; Wei W; Lin M
    Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):85-6. PubMed ID: 11809105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls.
    Voelkerding KV; Wu L; Williams EC; Hoffman SM; Sabatini LM; Borcherding WR; Huber S
    Am J Clin Pathol; 1996 Jul; 106(1):100-6. PubMed ID: 8701917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.
    Marzo C; Araguás C; Gómez-Arbonés J; Ramírez S
    Haematologica; 1998 Apr; 83(4):377-8. PubMed ID: 9592990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombotic risk during pregnancy and puerperium in women with APC-resistance--effective subcutaneous heparin prophylaxis in a pregnant patient.
    De Stefano V; Mastrangelo S; Paciaroni K; Ireland H; Lane DA; Scirpa P; Bizzi B; Leone G
    Thromb Haemost; 1995 Aug; 74(2):793-4. PubMed ID: 8585024
    [No Abstract]   [Full Text] [Related]  

  • 37. Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
    Zotz RB; Gerhardt A; Kluft C; Scharf RE
    Thromb Haemost; 2005 Feb; 93(2):306-10. PubMed ID: 15711747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Activated protein C resistance as a cause of thrombophilia].
    Ruiz-Argüelles GJ
    Rev Invest Clin; 1996; 48(3):223-9. PubMed ID: 8966383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Technical and biological conditions influencing the functional APC resistance test.
    Freyburger G; Bilhou-Nabera C; Dief S; Javorschi S; Labrouche S; Lerebeller MJ; Boisseau MR
    Thromb Haemost; 1996 Mar; 75(3):460-5. PubMed ID: 8701408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
    Yossepowitch O; Chajek-Shaul T; Rubinow A; Haviv YS; Safadi R
    Eur J Med Res; 1997 Aug; 2(8):355-7. PubMed ID: 9262489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.